From the publishers of JADPRO

Acute Lymphoblastic Leukemia Resource Center

Advertisement

Exploring the financial burden of pediatric bone marrow transplantation: A cross-sectional study from the caregiver's viewpoint

Last Updated: Tuesday, February 25, 2025

This study assessed the financial burden of hematopoietic cell transplantation on caregivers of pediatric patients. The cross-sectional study interviewed 257 caregivers. Researchers found that 92% of caregivers spent all bank savings, and 67% sold assets to cover expenses. About 18% had to take leave from work for the treatment. The study concludes that financial burdens are substantial, leading to economic impacts and a lower quality of life. It suggests policy and insurance reforms are needed.

BMC Health Services Research
Advertisement
News & Literature Highlights

Discover Oncology

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: A case series and literature review

Frontiers in Oncology

Impact of standardized immunophenotyping and MRD monitoring on early mortality reduction in childhood leukemia: A step towards addressing healthcare disparities in vulnerable populations from Southern Mexico

Clinical and Experimental Pediatrics

Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed/ refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis

Medical Journal, Armed Forces India

Bone mineral density in childhood acute lymphoblastic leukaemia survivors and factors affecting it

Blood Advances

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Pediatrics International: Official Journal of the Japan Pediatric Society

Safety and efficacy of sedation for pediatric patients with cancer and developmental disabilities

BMC Ophthalmology

Daratumumab-induced acute angle closure glaucoma: bone marrow transplantation as a possible risk factor and atropinization as a potential solution

Leukemia

Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: A single-center, single-arm, phase 2 trial

Cancer

Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Clinical Laboratory

T-acute lymphoblastic leukemia/lymphoma manifesting as acute renal failure

Advertisement
Advertisement